In this study, we examined stromal p16 expression in benign, borderline, and malignant ovarian neoplasms by immunohistochemistry to determine whether a significant difference exists in stromal p16 immunoreactivity according to degree of malignancy and/or histological type. The gene discussed is CDKN2A; the disease is ovarian cancer.